Literature DB >> 12237296

Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.

Joseph G Joyce1, William M Hurni, Michael J Bogusky, Victor M Garsky, Xiaoping Liang, Michael P Citron, Renee C Danzeisen, Michael D Miller, John W Shiver, Paul M Keller.   

Abstract

The synthetic peptide DP178, derived from the carboxyl-terminal heptad repeat region of human immunodeficiency virus type 1 GP41 protein is a potent inhibitor of viral-mediated fusion and contains the sequence ELDKWA, which constitutes the recognition epitope for the broadly neutralizing human monoclonal antibody 2F5. Efforts at eliciting a 2F5-like immune response by immunization with peptides or fusion proteins containing this sequence have not met with success, possibly because of incorrect structural presentation of the epitope. Although the structure of the carboxyl-terminal heptad repeat on the virion is not known, several recent reports have suggested a propensity for alpha-helical conformation. We have examined DP178 in the context of a model for optimized alpha-helices and show that the native sequence conforms poorly to the model. Solution conformation of DP178 was studied by circular dichroism and NMR spectroscopy and found to be predominantly random, consistent with previous reports. NMR mapping was used to show that the low percentage of alpha-helix present was localized to residues Glu(662) through Asn(671), a region encompassing the 2F5 epitope. Using NH(2)-terminal extensions derived from either GP41 or the yeast GCN4 leucine zipper dimerization domain, we designed peptide analogs in which the average helicity is significantly increased compared with DP178 and show that these peptides exhibit both a modest increase in affinity for 2F5 using a novel competitive solution-based binding assay and an increased ability to inhibit viral entry in a single-cycle infectivity model. Selected peptides were conjugated to carrier protein and used for guinea pig immunizations. High peptide-specific titers were achieved using these immunogens, but the resulting sera were incapable of viral neutralization. We discuss these findings in terms of structural and immunological considerations as to the utility of a 2F5-like response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237296     DOI: 10.1074/jbc.M205862200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Small molecule mimetics of an HIV-1 gp41 fusion intermediate as vaccine leads.

Authors:  Michael J Caulfield; Vadim Y Dudkin; Elizabeth A Ottinger; Krista L Getty; Paul D Zuck; Robin M Kaufhold; Robert W Hepler; Georgia B McGaughey; Michael Citron; Renee C Hrin; Ying-Jie Wang; Michael D Miller; Joseph G Joyce
Journal:  J Biol Chem       Date:  2010-10-13       Impact factor: 5.157

3.  Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

Authors:  Elisabetta Bianchi; Marco Finotto; Paolo Ingallinella; Renee Hrin; Anthony V Carella; Xiaoli S Hou; William A Schleif; Michael D Miller; Romas Geleziunas; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-29       Impact factor: 11.205

4.  A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Authors:  Michael D Miller; Romas Geleziunas; Elisabetta Bianchi; Simon Lennard; Renee Hrin; Hangchun Zhang; Meiqing Lu; Zhiqiang An; Paolo Ingallinella; Marco Finotto; Marco Mattu; Adam C Finnefrock; David Bramhill; James Cook; Debra M Eckert; Richard Hampton; Mayuri Patel; Stephen Jarantow; Joseph Joyce; Gennaro Ciliberto; Riccardo Cortese; Ping Lu; William Strohl; William Schleif; Michael McElhaugh; Steven Lane; Christopher Lloyd; David Lowe; Jane Osbourn; Tristan Vaughan; Emilio Emini; Gaetano Barbato; Peter S Kim; Daria J Hazuda; John W Shiver; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

Review 5.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

6.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.

Authors:  Florence M Brunel; Michael B Zwick; Rosa M F Cardoso; Josh D Nelson; Ian A Wilson; Dennis R Burton; Philip E Dawson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 8.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

9.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

Authors:  Joshua S Klein; Priyanthi N P Gnanapragasam; Rachel P Galimidi; Christopher P Foglesong; Anthony P West; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

Review 10.  Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study.

Authors:  Joachim Denner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.